At the time of writing, Biogen Inc [BIIB] stock is trading at $137.08, up 0.29%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BIIB shares have gain 2.74% over the last week, with a monthly amount drifted -2.77%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biogen Inc [NASDAQ: BIIB] stock has seen the most recent analyst activity on February 11, 2025, when Bernstein initiated its Mkt Perform rating and assigned the stock a price target of $160. Previously, Piper Sandler downgraded its rating to Neutral on January 02, 2025, and dropped its price target to $138. On December 20, 2024, downgrade downgraded it’s rating to Market Perform and revised its price target to $164 on the stock. Stifel downgraded its rating to a Hold but stick to its price target of $175 on December 16, 2024. Jefferies downgraded its rating to Hold for this stock on December 09, 2024, and downed its price target to $180. In a note dated November 18, 2024, Needham downgraded an Hold rating on this stock.
For the past year, the stock price of Biogen Inc fluctuated between $128.51 and $238.00. Currently, Wall Street analysts expect the stock to reach $233.92 within the next 12 months. Biogen Inc [NASDAQ: BIIB] shares were valued at $137.08 at the most recent close of the market. An investor can expect a potential return of 70.64% based on the average BIIB price forecast.
Analyzing the BIIB fundamentals
According to Biogen Inc [NASDAQ:BIIB], the company’s sales were 9.27B for trailing twelve months, which represents an 1.66% jump. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at 0.31%, Pretax Profit Margin comes in at 0.2%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.1 and Total Capital is 0.13. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.28.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 136.09 points at the first support level, and at 135.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 138.51, and for the 2nd resistance point, it is at 139.93.
Ratios To Look Out For
It is important to note that Biogen Inc [NASDAQ:BIIB] has a current ratio of 1.35. Also, the Quick Ratio is 0.90, while the Cash Ratio stands at 0.43. Considering the valuation of this stock, the price to sales ratio is 2.17, the price to book ratio is 1.20 and price to earnings (TTM) ratio is 12.26.
Transactions by insiders
Recent insider trading involved Singhal Priya, Head of Development, that happened on Dec 09 ’24 when 110.0 shares were sold. Officer, Singhal Priya completed a deal on Dec 09 ’24 to buy 110.0 shares. Meanwhile, Head of Development Singhal Priya sold 431.0 shares on Sep 03 ’24.
